Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq deficiency: closing bid below $1.00 for 30 consecutive trading days through June 24, 2026.
- This filing includes Item 3.01, an item that often signal trouble.
HERON THERAPEUTICS, INC. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq deficiency: closing bid below $1.00 for 30 consecutive trading days through June 24, 2026
- HRTX retains Nasdaq Capital Market listing and trading under “HRTX” during the compliance period
- Initial cure deadline: December 22, 2026, requiring at least $1.00 closing bid for 10 consecutive days
- Potential additional 180-day period, possibly requiring a reverse stock split if initial compliance fails
- Delisting risk remains if HRTX cannot restore bid-price compliance or satisfy other Nasdaq requirements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HERON THERAPEUTICS, INC. /DE/ 8-K filings
Get the next HRTX 8-K as it lands
Follow HRTX for push alerts, or ask the research agent what this filing means.